PDCD1 and nasopharyngeal carcinoma: Immune checkpoint inhibitors (ICIs), which target inhibitory receptors such as PD−1, CTLA−4, and LAG−3, aim to reinvigorate antitumor T cell responses and have shown encouraging activity in NPC.53–56